Pasithea Therapeutics CORP Form 4 insider transactions

Pasithea Therapeutics Corp. reports the grant of stock options to CEO Tiago Marques, with specific vesting conditions and a 10-year expiration.

Pasithea Therapeutics Corp. reports that Director Lawrence Steinman was granted stock options exercisable at $0.84, vesting in full on May 1, 2026, or upon a Change in Control.

Pasithea Therapeutics Corp. reports that Director Simon Dumesnil was granted stock options under the company's 2023 Stock Incentive Plan.

Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp., was granted stock options under the company's 2023 Stock Incentive Plan.

Kartik Krishnan, Chief Medical Officer of Pasithea Therapeutics Corp., received a stock option grant for 1,129,323 shares.

Pasithea Therapeutics Corp. reports a Form 4 filing detailing the grant of stock options to Director Emer Leahy.

Pasithea Therapeutics Corp. director Alfred J. Novak was granted stock options exercisable at $0.84 per share, vesting in one year or upon a change in control.

Pasithea Therapeutics Corp. Director and 10% owner Lawrence Steinman acquired 133,333 shares of common stock at $0.75 per share, increasing his direct beneficial ownership to 199,691 shares.

Pasithea Therapeutics Corp.'s Chief Financial Officer, Daniel H. Schneiderman, acquired 26,667 shares of common stock at $0.75 per share.

Pasithea Therapeutics Corp. CEO Tiago Marques acquired 33,333 shares of common stock at $0.75 per share, increasing his direct beneficial ownership to 73,334 shares.

Pasithea Therapeutics Corp. Director Simon Dumesnil acquired 33,333 shares of common stock at $0.75 per share.

Pasithea Therapeutics Director Emer Leahy acquired 33,333 shares of common stock at $0.75 per share.

Pasithea Therapeutics Director Lawrence Steinman received a grant of 242,913 stock options with an exercise price of $0.715, vesting over one year.

Pasithea Therapeutics Corp.'s Chief Financial Officer, Daniel H. Schneiderman, was granted 317,266 stock options with an exercise price of $0.715.

Pasithea Therapeutics Director Alfred J. Novak was granted 42,913 stock options with an exercise price of $0.715, vesting over one year.

Pasithea Therapeutics CEO Tiago Marques received a grant of 493,341 stock options with an exercise price of $0.715, vesting over three years.

Pasithea Therapeutics Director Emer Leahy received an award of 42,913 stock options with an exercise price of $0.715, vesting over one year.

Pasithea Therapeutics Corp. Director Simon Dumesnil was granted 42,913 stock options with an exercise price of $0.715, vesting over one year.

Pasithea Therapeutics CEO Tiago Marques sold 960 shares of common stock at $0.825 per share due to the closure of a foreign brokerage account.

Director Alfred J. Novak reported purchasing additional shares of Pasithea Therapeutics Corp. (KTTA) on June 12 and 13, 2024.

Tiago Marques, CEO of Pasithea Therapeutics, files an amended Form 4 to correct the exercise price of stock options granted on March 1, 2024.

Simon Dumesnil, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Daniel Schneiderman, CFO of Pasithea Therapeutics, files an amended Form 4 to correct the exercise price of stock options granted on March 1, 2024.

Emer Leahy, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Alfred J. Novak, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Graeme Currie, Chief Development Officer of Pasithea Therapeutics, files an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Lawrence Steinman, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Lawrence Steinman, a director of Pasithea Therapeutics Corp., was granted stock options to purchase 7,500 shares of common stock on March 1, 2024.

Daniel Schneiderman, CFO of Pasithea Therapeutics, reports acquisition of stock options in the company.

Director Alfred J. Novak acquired 5,000 stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing.